Bright.md announced that it closed Series C funding, bringing in strategic investors including Philips Health Technology Ventures, UnityPoint Health Ventures and Concord Health Partners, a healthcare-focused investment firm that has partnered with the American Hospital Association (AHA) on its AHA Innovation Development Fund. The company has raised $16.7 million in its oversubscribed Series C round co-led by B Capital, Seven Peaks Ventures and Concord Health Partners.
Bright.md will use the funding for accelerated market and technology expansion of its suite of care-automation solutions, including their award-winning flagship product, SmartExam™, a capacity-boosting, AI-powered, asynchronous telehealth platform already deployed in leading hospitals and healthcare systems across the U.S. and Canada.
“Providers across the country have witnessed a decline in ambulatory visits as a result of shelter-in-place orders. At the same time other systems are overrun with COVID-19 patients,” said Ray Costantini, M.D., co-founder and CEO of Bright.md.
“In one region, clinicians are being furloughed and in other systems they are being pushed beyond capacity. SmartExam gives providers the necessary support they will need to help triage and treat, and offers patients a digital entrypoint to help them efficiently navigate the system in an environment where many fear doctor visits because of exposure to COVID-19. The coronavirus has only expedited a trend in care delivery that has been underway for nearly a decade.”
Q32 Bio has closed a $46 million Series A round to support the launch of the biotech business. Its lead product is an antibody, licensed from Bristol Myers Squibb, to treat patients with severe autoimmune and inflammatory disease. Atlas Venture led the round with participation from OrbiMed Advisors, Abingworth, Sanofi Ventures, and University of Colorado and Children’s Hospital Colorado Center for Innovation. Click here to read more.
Siren, which makes socks embedded with sensors to support early detection of diabetic ulcers, has raised a $11.8 million Series B funding round led by Anathem Ventures. Other investors that took part in the funding include DCM, Khosla Ventures, 500 Startups, and Peter Thiel’s Founders Fund. Among other companies active in the area of remote detection of diabetic foot ulcers are Podimetrics, MR3 Health, and Orpyx. Click here to read more.
Want to promote a webcast, podcast or virtual networking event to our readers? Contact Mary Aikoriegie on MedCity’s sales team to promote your event in the virtual events section of the website and in our newsletters at [email protected]
Picture: akindo, Getty Images
